Recruiting

Diabetes Sensors

Sponsor:

Medtronic MiniMed, Inc.

Code:

NCT07864168

Conditions

Type 1 Diabetes

Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 2 - 70+

Healthy Volunteers: Not accepted

Interventions

Next Generation Extended Wear Sensors

Study Details

Brief summary:

This study will collect sensor data in subjects with T1D or T2D, 2-80 years of age.

Conditions

Type 1 Diabetes

Type 2 Diabetes

Study ID

NCT07864168

Start date

Oct, 2026

Status verified date

Oct, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 2 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age 2-80 years at time of screening.
2. Has a clinical diagnosis of diabetes as stipulated according to the following age group:

1. Age 2-10 years: Has a clinical diagnosis of T1D or T2D as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
2. Age 11-80 years: Has a clinical diagnosis of T1D or T2D for 6 months or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
3. Subject or parent(s)/ guardian(s)/ caregiver(s) is/are literate and able to read the language offered in the study materials.
4. Is willing to provide informed consent/assent for participation.
5. If participating in BGA FST, has adequate venous access as assessed by investigator or appropriate staff.
6. Is willing to perform fingerstick blood glucose measurements as needed.
7. Is willing to wear the study devices continuously throughout the study.
8. Subject or parent(s)/guardian(s)/caregiver(s) is/are willing to complete the requirements for diary data entry, as applicable.
9. If participating in glycemic challenges, has met the following conditions:

1. Been using insulin for at least 3 months
2. A relatively stable insulin-to-carbohydrate ratio(s) and insulin sensitivity factor(s) for at least one month per investigator assessment Subjects who do not meet the above conditions can be included in the study, however, will participate in the FST under observation only (no glycemic challenges).

Exclusion Criteria:

1. Unable to consent due to a mental or intellectual disability.
2. Has a history of 1 or more episodes of severe hypoglycemia during the 6 months prior to screening visit.
3. Has had a hypoglycemic seizure within the past 6 months prior to screening visit.
4. Has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
5. Has a history of 1 or more episodes of DKA in the last 6 months prior to screening visit.
6. T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.
7. Has a history of a seizure disorder.
8. Has a central nervous system or cardiac disorder resulting in syncope.
9. Will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.
10. Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
11. Currently pregnant or planning to become pregnant during the time period of study participation

1. A negative pregnancy test will be required for all females of child-bearing potential at time of screening
2. For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of contraception that is being used is reliable
12. Has diagnosis of adrenal insufficiency.
13. Is using hydroxyurea at time of screening or plans to use it during the study.
14. Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study. (Please note participation in an observational study is acceptable.)
15. Has a planned procedure involving the use of a Magnetic Resonance Imaging (MRI), diathermy devices, or other devices that generate strong magnetic fields (e.g., x-ray, CT scan, or other types of radiation) during the study wear period.
16. Has elective surgery planned that requires general anesthesia during the course of the study.
17. T2D: Is using insulin secretagogue.
18. Is, at the discretion of the investigator, abusing drugs or alcohol
19. Age 7-80 years: has a hematocrit (Hct) more than 10% below the lower limit of normal reference range (please note that prior blood draw from routine care may be used as long as the prior blood draw was done within 3 months prior to screening and report of lab placed with subject source documents).
20. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.
21. Has had any of the following cardiovascular events more than 1 year prior to screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances. However, subject may participate at the discretion of the investigator and with clearance from the cardiologist.
22. Has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.
23. Is a member of the research staff involved with the study.
24. Is a sponsor employee or their immediate family member (excluding adult children and/or adult siblings).

Study Design

Enrollment

1500 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Next Generation Extended Wear Sensors

All subjects will wear the sensor. Each subject and subject's parent/guardian/caregiver (if applicable) may insert and tape (if applicable) the study glucose sensors once trained or have them inserted and taped (if applicable) by the trained investigational center staff.

Interventions

Next Generation Extended Wear Sensors

Disposable Sensor (MMT-5600XNG and MMT-5600X) - labeled as DS5K and referred to as Unity

Primary outcome measure

  • Primary Safety Endpoints [ Time Frame: Approximately up to 46 days ]

Central Contacts and Locations

Central contacts

Locations

Barbara Davis Center for Diabetes

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Principal Investigator:

Satish Garg

Atlanta Diabetes Associates

Recruiting

Atlanta, Georgia, United States, 30318

Contacts

Principal Investigator:

Bruce Bode

Rocky Mountain Clinical Research

Recruiting

Idaho Falls, Idaho, United States, 83404

Contacts

Principal Investigator:

David Liljenquist

Rainier Clinical Research Center

Recruiting

Renton, Washington, United States, 98057

Contacts

Principal Investigator:

Sheryl Marks

More Information

Sponsor

Medtronic MiniMed, Inc.

Last update posted

Oct 7, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-08. This information was provided to ClinicalTrials.gov by Medtronic MiniMed, Inc. on 2026-10-07. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.